RT Book, Section
A1 Smith, Matthew R.
A2 Chabner, Bruce A.
A2 Longo, Dan L.
SR Print(0)
ID 1127647081
T1 Osteoclast-Targeted Therapy: Bisphosphonates and Denosumab
T2 Harrison's Manual of Oncology, 2e
YR 2016
FD 2016
PB McGraw-Hill Education
PP New York, NY
SN 9780071793254
LK hemonc.mhmedical.com/content.aspx?aid=1127647081
RD 2024/04/23
AB Bone  metastases  are  a  major  cause  of  morbidity  in  patients  with  a  variety  of  malignancies  including  multiple  myeloma,  breast  cancer,  and  prostate  cancer  (1).  Bone  metastases  are  often  described  as  osteoblastic  or  osteolytic  based  on  their  radiographic  appearance.  Osteoblastic  and  osteolytic  bone  disease  represent  two  extremes  of  a  spectrum,  however,  and  osteoclast  number  and  activity  are  increased  in  most  bone  metastases,  including  typical  osteoblastic  metastases  from  prostate  cancer.  Pathological  activation  of  osteoclasts  appears  to  play  a  central  role  in  disease-related  skeletal  complications.